CompareMarketResearchRequest a sample
Home / Healthcare / AI-Assisted Clinical Trial Protocol Design

Healthcare · Market report

AI-Assisted Clinical Trial Protocol Design Market Size, Share and Forecast 2026-2036

The global AI-assisted clinical trial protocol design market is worth USD 378 mn in 2026 and is forecast to reach USD 2.3 bn by 2036, growing at a 20.0% CAGR. United States is the largest country market and Protocol optimisation analytics is the largest by solution segment.

USD 378 mnMarket size 2026
USD 2.3 bnForecast 2036
20.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global AI-assisted clinical trial protocol design market is worth USD 378 mn in 2026 and is forecast to reach USD 2.3 bn by 2036, growing at a 20.0% CAGR. United States is the largest country market and Protocol optimisation analytics is the largest by solution segment.

ScopeSoftware and services that use AI to design, optimise and simulate clinical trial protocols: eligibility criteria, endpoints, site and patient feasibility, synthetic control arms and generative protocol drafting.
IndustryHealthcare
Value 2025USD 310 mn
Value 2026USD 378 mn
Value 2036USD 2.3 bn
CAGR 2026-203620.0%
Volume 202610.9 thousand protocol designs
Volume 203660.9 thousand protocol designs
Average price 2026USD 34,790 per protocol design
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

AI-Assisted Clinical Trial Protocol Design market size and forecast, 2026-2036

Exhibit 1The global AI-assisted clinical trial protocol design market is forecast to grow from USD 378 mn in 2026 to USD 2.3 bn by 2036, more than five times its 2026 sizeGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 20.0%
AI-Assisted Clinical Trial Protocol Design market value, 2025 to 2036Market value by year. 2025: USD 310 mn; 2026: USD 378 mn; 2027: USD 454 mn; 2028: USD 545 mn; 2029: USD 654 mn; 2030: USD 784 mn; 2031: USD 941 mn; 2032: USD 1.1 bn; 2033: USD 1.4 bn; 2034: USD 1.6 bn; 2035: USD 2.0 bn; 2036: USD 2.3 bn. Compound annual growth rate 2026 to 2036: 20.0%.2025378 mn2026941 mn20312.3 bn203620.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 378 mn
2027USD 454 mn
2028USD 545 mn
2029USD 654 mn
2030USD 784 mn
2031USD 941 mn
2032USD 1.1 bn
2033USD 1.4 bn
2034USD 1.6 bn
2035USD 2.0 bn
2036USD 2.3 bn

AI-Assisted Clinical Trial Protocol Design market segmentation

By solution

Exhibit 2Protocol optimisation analytics is the largest segment by solution, with 42.0% of 2026 revenueEstimated share of 2026 global revenue, by solution
AI-Assisted Clinical Trial Protocol Design market share by solution, 2026Share of 2026 revenue by solution. Protocol optimisation analytics: 42.0%; Synthetic control arms and simulation: 24.0%; Site and patient feasibility modelling: 20.0%; Generative protocol authoring: 14.0%.Protocol optimisation analytics42.0%Synthetic control arms and simulation24.0%Site and patient feasibility modelling20.0%Generative protocol authoring14.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Protocol optimisation analytics42.0%33.0%USD 159 mn17.1%
Synthetic control arms and simulation24.0%28.5%USD 91 mn22.1%
Site and patient feasibility modelling20.0%15.7%USD 76 mn17.1%
Generative protocol authoring14.0%22.8%USD 53 mn26.0%

By end user

Exhibit 3Pharmaceutical companies adds the most revenue by end user, growing from USD 234 mn in 2026 to USD 1.3 bn by 2036Estimated revenue in USD by end user, 2026 and 2036 forecast
AI-Assisted Clinical Trial Protocol Design market by end user, 2026 and 2036Revenue by end user in 2026 and 2036. Pharmaceutical companies: USD 234 mn in 2026, USD 1.3 bn in 2036, change +449%; Biotechnology companies: USD 83 mn in 2026, USD 692 mn in 2036, change +732%; Contract research organisations: USD 61 mn in 2026, USD 362 mn in 2036, change +498%.20262036 forecastChangePharmaceutical companies+449%234 mn1.3 bnBiotechnology companies+732%83 mn692 mnContract research organisations+498%61 mn362 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Pharmaceutical companies62.0%55.0%USD 234 mn18.6%
Biotechnology companies22.0%29.6%USD 83 mn23.6%
Contract research organisations16.0%15.4%USD 61 mn19.6%

By trial phase

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Early phase16.0%17.0%USD 61 mn20.7%
Phase two34.0%34.0%USD 129 mn20.0%
Phase three40.0%39.0%USD 151 mn19.7%
Post-marketing studies10.0%10.0%USD 38 mn20.0%

By therapeutic area

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Oncology40.0%40.0%USD 151 mn20.0%
Neurology and psychiatry18.0%19.0%USD 68 mn20.6%
Rare diseases14.0%16.0%USD 53 mn21.6%
Cardiometabolic and infectious disease28.0%25.0%USD 106 mn18.6%

By deployment

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Cloud56.0%60.0%USD 212 mn20.8%
Private cloud24.0%23.0%USD 91 mn19.5%
On-premise20.0%17.0%USD 76 mn18.1%

Top 25 countries for AI-assisted clinical trial protocol design by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 88.0% of 2026 revenue and the 25 countries below together hold 96.8%.

Exhibit 4United States is the largest country market at USD 189 mn in 2026, and the three largest countries hold 63.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
AI-Assisted Clinical Trial Protocol Design market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 189 mn, 50.0%; United Kingdom: USD 26 mn, 7.0%; Germany: USD 23 mn, 6.0%; China: USD 23 mn, 6.0%; France: USD 15 mn, 4.0%; Japan: USD 15 mn, 4.0%; Switzerland: USD 15 mn, 4.0%; Canada: USD 11 mn, 3.0%; Netherlands: USD 7.6 mn, 2.0%; India: USD 7.6 mn, 2.0%.United States189 mn 50.0%United Kingdom26 mn 7.0%Germany23 mn 6.0%China23 mn 6.0%France15 mn 4.0%Japan15 mn 4.0%Switzerland15 mn 4.0%Canada11 mn 3.0%Netherlands7.6 mn 2.0%India7.6 mn 2.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 189 mn50.0%USD 1.2 bn20.0%
2United KingdomUSD 26 mn7.0%USD 157 mn19.5%
3GermanyUSD 23 mn6.0%USD 129 mn19.0%
4ChinaUSD 23 mn6.0%USD 166 mn22.0%
5FranceUSD 15 mn4.0%USD 87 mn19.1%
6JapanUSD 15 mn4.0%USD 82 mn18.4%
7SwitzerlandUSD 15 mn4.0%USD 89 mn19.4%
8CanadaUSD 11 mn3.0%USD 68 mn19.6%
9NetherlandsUSD 7.6 mn2.0%USD 44 mn19.4%
10IndiaUSD 7.6 mn2.0%USD 61 mn23.2%
11SpainUSD 3.0 mn0.8%USD 18 mn19.5%
12ItalyUSD 3.0 mn0.8%USD 18 mn19.5%
13BelgiumUSD 2.7 mn0.7%USD 16 mn19.5%
14DenmarkUSD 2.7 mn0.7%USD 16 mn19.5%
15AustraliaUSD 2.7 mn0.7%USD 16 mn19.5%
16South KoreaUSD 2.7 mn0.7%USD 18 mn20.8%
17SwedenUSD 2.4 mn0.6%USD 14 mn19.6%
18IrelandUSD 2.4 mn0.6%USD 14 mn19.6%
19IsraelUSD 2.1 mn0.6%USD 14 mn20.9%
20SingaporeUSD 1.8 mn0.5%USD 12 mn21.0%
21AustriaUSD 1.8 mn0.5%USD 11 mn19.5%
22BrazilUSD 1.5 mn0.4%USD 11 mn21.9%
23PolandUSD 1.5 mn0.4%USD 9.8 mn20.6%
24TaiwanUSD 1.5 mn0.4%USD 9.8 mn20.6%
25NorwayUSD 1.5 mn0.4%USD 8.9 mn19.4%
Rest of worldUSD 12 mn3.2%USD 80 mn20.7%
Exhibit 5United States and China account for 57% of the USD 2.0 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
AI-Assisted Clinical Trial Protocol Design market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 378 mn. United States: +USD 984 mn; China: +USD 144 mn; United Kingdom: +USD 130 mn; Germany: +USD 106 mn; Switzerland: +USD 74 mn; 20 other countries: +USD 458 mn; Rest of world: +USD 68 mn. Market value 2036: USD 2.3 bn.Market value 2026378 mnUnited States+984 mnChina+144 mnUnited Kingdom+130 mnGermany+106 mnSwitzerland+74 mn20 other countries+458 mnRest of world+68 mnMarket value 20362.3 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • IQVIA
  • Medidata
  • Citeline
  • Parexel
  • ICON
  • Veeva Systems

Group 2: Regional and specialist players

  • Saama Technologies
  • Unlearn
  • Cytel
  • H1
  • Phesi
  • Lokavant
  • TriNetX

Group 3: Emerging and niche players

  • Faro Health
  • Intelligencia AI
  • Formation Bio

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the AI-assisted clinical trial protocol design market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 20.0% is calculated from the resulting values.

The market is divided by solution, by end user, by trial phase, by therapeutic area, by deployment. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the AI-assisted clinical trial protocol design market?

The global AI-assisted clinical trial protocol design market is estimated at USD 310 mn in 2025 and USD 378 mn in 2026.

How fast will the AI-assisted clinical trial protocol design market grow?

It is forecast to reach USD 2.3 bn by 2036, a compound annual growth rate of 20.0% from 2026, an increase of USD 2.0 bn.

Which country is the largest market for AI-assisted clinical trial protocol design?

United States is the largest market by revenue at USD 189 mn in 2026, 50.0% of the global total. The three largest countries together hold 63.0%.

Which country is growing fastest?

Among the ten largest markets, India is growing fastest at 23.2% a year from 2026 to 2036.

Which AI-assisted clinical trial protocol design segment is largest?

In the by solution split, Protocol optimisation analytics is the largest segment with 42.0% of 2026 revenue.

Who are the leading AI-assisted clinical trial protocol design companies?

Global leaders include IQVIA, Medidata, Citeline, Parexel.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← AI-Accelerated Nonclinical Drug Testing AI-Driven Cardiac Diagnostics →

All Healthcare markets →

Request a sample